Comparing Innoviva (INVA) & The Competition
Innoviva (NASDAQ: INVA) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Innoviva to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, profitability, earnings, dividends and valuation.
This table compares Innoviva and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Innoviva has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, Innoviva’s rivals have a beta of 32.56, suggesting that their average stock price is 3,156% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Innoviva and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Innoviva presently has a consensus price target of $13.00, indicating a potential upside of 5.69%. As a group, “Pharmaceuticals” companies have a potential upside of 21.40%. Given Innoviva’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Innoviva has less favorable growth aspects than its rivals.
Insider & Institutional Ownership
69.7% of Innoviva shares are owned by institutional investors. Comparatively, 42.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.6% of Innoviva shares are owned by company insiders. Comparatively, 11.7% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Innoviva and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Innoviva||$133.57 million||$59.53 million||14.14|
|Innoviva Competitors||$8.39 billion||$1.12 billion||133.49|
Innoviva’s rivals have higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Innoviva rivals beat Innoviva on 9 of the 13 factors compared.
Innoviva Company Profile
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.